| Literature DB >> 31565110 |
Timothy S H Kwok1, Natasha Gakhal2,3, Thanu N Ruban3,4.
Abstract
BACKGROUND: Patients who have suffered fragility fractures are at an increased risk for subsequent fractures. The Osteoporosis (OP) Clinic at Markham Stouffville Hospital (MSH) was set up in July 2015 to screen, diagnose, and treat patients with fragility fractures. The goal of this study was to identify differences in OP screening and treatment initiation between patients seen in the OP clinic versus usual care.Entities:
Keywords: community medicine; osteoporosis; quality improvement
Year: 2019 PMID: 31565110 PMCID: PMC6715410 DOI: 10.5770/cgj.22.359
Source DB: PubMed Journal: Can Geriatr J ISSN: 1925-8348
FIGURE 1Inclusion/exclusion flowchart of the Osteoporosis Clinic and Usual Care groups
Baseline demographic information and bisphosphonate/RANKL inhibitor use for patients in the Osteoporosis Clinic and Usual Care groups
| Age | 79.3 (58–97) | 81.5 (69–93) |
| Sex (F:M) | 16:4 | 15:5 |
| Bisphosphonate/RANKL inhibitor prior to fragility fracture | 4 | 5 |
Clinical parameters and telephone survey responses for patients in the Osteoporosis Clinic group (n=20)
| Osteoporosis Risk Factors | Menopausal | 16 |
| Average number of previous fragility fractures | 1.5 (1–2) | |
| Patients with parental fractured hip | 1 | |
| Currently smoking | 1 | |
| Glucocorticoid use | 2 | |
| Rheumatoid arthritis | 0 | |
| Alcohol use (>3 drinks/wk) | 1 | |
|
| ||
| Osteoporosis Clinic Intervention Information | Wait-time to see Osteoporosis Clinic physician (days) | 63.7 (8–20) |
| Bone mineral density (BMD) testing post-fragility fracture | 20 | |
| Average BMD | −2.28 (−0.2–−3.9) | |
| Bisphosphonate/RANKL inhibitor prescribed | 12 | |
| Bisphosphonate | 9/12 | |
| RANKL inhibitor | 3/12 | |
| Osteoporosis pharmacotherapy post-fragility fracture | 16 | |
| Medication adherence 3-months post-treatment initiation | 12/16 | |
Including current fragility fracture.
Lowest T-score at all sites.
Demographic information, clinical parameters, and telephone survey responses for patients in the Usual Care group (n=20)
| Reason patient not seen at Osteoporosis Clinic | No referral opportunity given: 8 |
| Primary care provider managing osteoporosis care: 2 | |
| Patient did not feel a need: 2 | |
| Distance of clinic: 1 | |
| Orthopaedic surgeon recommended against: 1 | |
| Transferred from another hospital: 1 | |
| More comfortable with primary care provider: 1 | |
| Treatment at another facility: 1 | |
| Family physician follow-up post-fracture | 19 |
| BMD testing post-fragility fracture | 10 |
| Bisphosphonate/RANKL inhibitor post-fragility fracture | 6 |
| Bisphosphonate | 4/6 |
| RANKL inhibitor | 2.6 |